Abstract
The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Current Pharmaceutical Design
Title: Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Volume: 14 Issue: 4
Author(s): Cecil S. Thompson
Affiliation:
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Abstract: The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Export Options
About this article
Cite this article as:
Thompson S. Cecil, Animal Models of Diabetes Mellitus: Relevance to Vascular Complications, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497679
DOI https://dx.doi.org/10.2174/138161208783497679 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design Neonatal Necrotizing Enterocolitis – Inflammation and Intestinal Immaturity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Risk Stratification of Dyslipidemia: Insights from the Framingham Study
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Interplay Between ACE2 and Angiotensin-(1-7) in the Regulation of Blood Pressure
Current Hypertension Reviews Natural Products as Potential Agents against SARS-CoV and SARSCoV- 2
Current Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Illuminating microRNA Transcription from the Epigenome
Current Genomics Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews Meet the Editorial Board
Current Vascular Pharmacology Patents on Metallic Biodegradable Stents
Recent Patents on Materials Science MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology